Butyrate triglyceride

Butyrate Triglyceride (Tributyrin): A Comprehensive Reference

1. Identity, Chemical Nomenclature, and Natural Sources

Chemical Identity

Tributyrin has the molecular formula C₁₅H₂₆O₆ (KEGG C13870; HMDB31094; CAS 60-01-5); its IUPAC name is 2,3-di[butanoyloxy]propyl butanoate. Alternative names include butanoic acid 1,2,3-propanetriyl ester, glycerol tributanoate, butyryl triglyceride, and glycerol tributyrate; its molecular weight is 302.36 g/mol. In plain language, tributyrin, or glyceryl tributyrate, is a triglyceride in which three butyric acid molecules are esterified to a glycerol backbone. Tributyrin is a triglyceride with butyrate molecules esterified at the 1, 2, and 3 positions.

While most butyrate salts (Na, K, Mg, Ca) are produced via an acid–base reaction to form salt with a high melting point (e.g., 250°C for sodium butyrate), tributyrin has a low melting point of −75°C. It is a naturally stable compound with the advantage of being non-volatile (practically odourless) and having fewer palatability issues than butyrate, and therefore does not require coating protection when added to food items.

Natural Occurrence

Tributyrin is a triglyceride naturally present in butter. It is an ester composed of butyric acid and glycerol, and it is present in butter and can be described as a liquid fat with an acrid taste. Tributyrin, a butyric acid prodrug present in milk fat and honey, has more favorable pharmacokinetic properties than butyric acid itself. Butyrate is produced when "good" bacteria in your gut help your body break down dietary fiber in your large intestine (colon), and it is one of several short-chain fatty acids, which are named for their chemical structure.

Tributyrin is synthesized through esterification of glycerol and butyric acid, occurring naturally in biological systems or via chemical and enzymatic methods. Enzymatic synthesis, catalyzed by lipases, is favored in industrial and pharmaceutical applications for its efficiency and specificity. In biological systems, tributyrin formation is rare but can occur under specific metabolic conditions. Some bacteria and fungi possess enzymes that esterify glycerol with short-chain fatty acids; yeast species such as Candida and Yarrowia can produce triglycerides, including tributyrin, through lipid metabolism.

Common Forms and Preparations

Supplements come as oral sodium/calcium/magnesium butyrate or as tributyrin (the triglyceride ester prodrug). Tributyrin is a naturally stable compound, practically odourless, and does not require coating protection when added to food items. In feed, tributyrin microencapsulation could further reduce bitterness while being released in a controlled manner, which could ameliorate feed intake-related impacts. Commercial branded tributyrin preparations available as dietary supplements include CoreBiome® (a patented, clinically studied form) and ButyraGen® (a tributyrin-containing complex studied in human pilot trials). Mixed triglyceride patents have also described new triglycerides composed of a mixture of butyrate and medium chain fatty acids (MCFAs), with improved odour and/or taste relative to butyric acid, butyrate salts, and tributyrin.

As a triglyceride, tributyrin is primarily used as a flavoring agent and emulsifier in the food industry, enhancing the taste and texture of products. Its ability to act as a fat substitute makes it valuable in low-fat and reduced-calorie formulations.

2. Traditional and Historical Use

Tributyrin as a discrete, named compound does not appear in classical herbal or ethnomedicinal traditions in the way that botanical extracts do. Its history is instead rooted in the millennial use of dairy foods — primarily butter, fermented milks, and cheeses — across cultures in which butyric acid glycerides are naturally present. Tributyrin is a triglyceride naturally present in butter, and is an ester composed of butyric acid and glycerol; among other things, it has been used as an ingredient in making margarine.

The scientific isolation and characterisation of butyric acid and its esters dates to the nineteenth century, when French chemist Michel Eugène Chevreul identified butyric acid in butter in the early 1800s. The name itself derives from the Latin butyrum, meaning butter. The triglyceride form (tributyrin) was subsequently identified as a naturally occurring component of milk fat. Salatrim, a fat calorie replacer commonly used in the food industry, is also a source of dietary butyrate; it has triglyceride mixtures in which butyric acid is inter-esterified with a long-chain fatty acid moiety such as stearic acid.

The pharmacological interest in butyrate and its prodrugs as therapeutic agents emerged in the 1970s–1990s, when researchers began to study butyrate as a differentiating and anti-neoplastic agent. Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies. Tributyrin was explored as a prodrug of butyric acid for potential clinical application in differentiation therapy from the mid-1990s onward. The first human phase I clinical trials of tributyrin as an oncology agent were published in the late 1990s.

3. Key Constituents and Mechanisms of Action

Active Compound: Butyrate

The primary active compound released from tributyrin is butyric acid (butanoic acid), a four-carbon short-chain fatty acid (SCFA). Tributyrin is a structured lipid with three butyrate molecules esterified to the glycerol backbone; upon oral ingestion, tributyrin is digested by pancreatic lipase to free up three butyrate molecules which are then absorbed throughout the intestine.

Pharmacokinetic Advantages Over Salt Forms

Because it is rapidly absorbed and chemically stable in plasma, tributyrin diffuses through biological membranes and is metabolized by intracellular lipases, releasing therapeutically effective butyrate over time directly into the cell. Compared with butyrate, tributyrin has more favorable pharmacokinetics and is well tolerated. Tributyrin survives gastric acid intact; lipase hydrolysis releases butyrate in the small intestine and proximal colon. In contrast, when supplemented orally, the majority of butyrate is absorbed in the small intestine and relatively little butyrate reaches the colon; tributyrin is a butyrate precursor that resists gastric acids to allow more butyrate to reach the colon.

In a validated in vitro upper gastrointestinal transit simulation, 40.9 and 48.7% of the tributyrin dose administered via the capsule or softgel, respectively, was hydrolyzed to butyrate in the small intestine; 59.1 and 51.3% remained stable and was available to enter the colon.

Primary Mechanisms of Action of Released Butyrate

Energy substrate for colonocytes: Butyrate oxidation in mature colonocytes (1) produces 70–80% of their energetic requirements, (2) prevents stem cell inhibition by limiting butyrate access to crypts, and (3) consumes oxygen, generating hypoxia and maintaining luminal anaerobiosis favorable to the microbiota.

Histone deacetylase (HDAC) inhibition: Short-chain fatty acids (SCFAs), such as butyrate, propionate, and acetate, produced by various bacterial communities of the microbiome mostly via anaerobic fermentation of dietary fibers, act as natural HDAC inhibitors. In particular, besides serving as energy source for colonocytes, butyrate elicits a wide array of beneficial effects for gut homeostasis including suppression of pathological inflammation. Butyrate as an HDAC inhibitor results in hyperacetylation of histone H3 with consequent chromatin relaxation and expression of genes otherwise silenced by HDAC activity.

G-protein coupled receptor activation: Butyrate stimulates the aryl hydrocarbon receptor (AhR), the GPR41 and GPR109A receptors, and inhibits HDAC in different cell types, thus stabilizing the gut barrier function and decreasing inflammatory processes.

Intestinal barrier integrity: Experimental studies demonstrate that butyrate supports colonocyte energy metabolism, strengthens tight-junction integrity, enhances mucin and antimicrobial peptide production, and promotes epithelial repair. These effects are mediated through immunomodulatory pathways, in particular involving G-protein–coupled receptor activation and histone deacetylase inhibition.

The "butyrate paradox" — opposing effects on normal vs. neoplastic cells: This phenomenon, known as the 'butyrate paradox,' reflects that butyrate supports physiological proliferation and regeneration of normal colonocytes, yet in dysplastic or malignant cells activates epigenetic pathways that suppress their growth. Colon cancer cells preferentially use glucose, rather than SCFA, as fuel for cellular function — an adaptation referred to as the Warburg effect. The dominance of glycolytic metabolism over oxidative phosphorylation in cancerous colonocytes allows butyrate to accumulate and act as an HDAC inhibitor, thereby halting cell cycle progression through altered gene expression. There is growing evidence that butyrate also directly binds and alters activity of metabolic enzymes in colon cancer cells, thus conferring a protective anti-neoplastic effect through reversal of the Warburg effect.

Anti-inflammatory immunomodulation: Butyrate suppressed TNF and IL-6 secretion by >50% in ex vivo-cultured inflamed IBD biopsies. Butyrate also suppressed IL-6, TNF-α, CD40, and CD80 by >50% and enhanced adherent-invasive Escherichia coli (AIEC) phagocytosis by 62% in monocytes/macrophages.

Hypoxia-inducible factor (HIF) stabilisation: Butyrate is a ligand for G-protein coupled receptors and it has been reported that butyrate either directly or indirectly activates the aryl hydrocarbon receptor transcription factor; it also stabilizes the transcription factor hypoxia-inducible factor (HIF), a master transcriptional regulator of many genes involved in intestinal homeostasis.

4. Scientific Evidence by Area of Use

4.1 Gastrointestinal Health and Intestinal Barrier Function

In vitro / gut-simulation evidence: A 2025 study published in Frontiers in Nutrition (PMC) evaluated tributyrin (CoreBiome®) using the validated Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) model. Using the SHIME® model, it was shown that 3 weeks of daily tributyrin supplementation increased butyrate levels and enhanced the abundance of several bacterial species, including Bifidobacterium spp. and Akkermansia mucinophila. Metabolic impacts on the gut microbiome were also observed; assessment of cellular responses revealed that tributyrin fermentation had a protective effect on the intestinal barrier and exerted immunomodulatory properties. The authors concluded that enhanced butyrate concentrations and beneficial impacts on the gut microbial community composition were observed in an in vitro simulation of the human intestinal environment, suggesting that tributyrin could be considered as a solid alternative to butyrate supplementation. This study is in vitro and cannot directly establish clinical outcomes in humans.

Pilot human clinical evidence: A 2024 randomised pilot study, the first randomised controlled study in free-living healthy adults, assessed a tributyrin-containing complex (ButyraGen®). The study aimed to evaluate the effect of tributyrin on tolerability, gut microbiome composition, gut permeability, inflammation, and metabolic markers in healthy adults at two dose levels. Healthy adults (n=29) were randomized to a single-blinded, two-arm, 28-day parallel design pilot study; participants ingested one or two (200 or 400 mg, respectively) ButyraGen® capsules daily for 21 days. The main findings were: (1) the supplement was well tolerated, (2) fecal acetic and propionic acids were decreased in the combined dose group analysis, (3) gut microbiota composition was unchanged. This study reported for the first time the effects of oral tributyrin supplementation in free-living, healthy adults in a randomized controlled study. Prior research included one non-randomized/non-controlled study in three people and two other clinical trials that investigated tributyrin supplementation in people with solid tumors at high pharmacological doses. All other known tributyrin supplement studies had been conducted in animal models. The study was limited by its small sample size and single-blinded design.

Inflammatory bowel disease (butyrate class): The broader clinical literature on oral butyrate (predominantly as sodium butyrate enemas and oral formulations, not specifically tributyrin) in IBD is more developed. Sodium butyrate has emerged as a promising adjunctive therapy in IBD; IBD is commonly associated with intestinal dysbiosis characterized by depletion of butyrogenic bacteria, leading to a functionally relevant butyrate deficiency that contributes to epithelial barrier dysfunction, immune dysregulation, and persistent mucosal inflammation. Clinically, sodium butyrate has shown therapeutic potential primarily in ulcerative colitis, with more limited data in Crohn's disease. Evidence specifically for oral tributyrin in IBD in humans remains limited.

4.2 Oncology and Differentiation Therapy

Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies. Tributyrin is a triglyceride with butyrate molecules esterified at the 1, 2, and 3 positions that induces differentiation and/or growth inhibition of a number of cell lines in vitro.

Phase I clinical trial — solid tumors (once-daily dosing, 1998): The first Phase I study, published in Clinical Cancer Research (1998), treated 13 patients with solid tumors. Patients received escalating doses of tributyrin from 50 to 400 mg/kg/day, administered orally after an overnight fast, once daily for 3 weeks, followed by a 1-week rest; intrapatient dose escalation occurred after two courses without toxicity greater than grade 2. Grade 3 toxicities consisted of nausea, vomiting, and myalgia; grades 1 and 2 toxicities included diarrhea, headache, abdominal cramping, nausea, anemia, constipation, azotemia, lightheadedness, fatigue, rash, alopecia, odor, dysphoria, and clumsiness. Peak plasma butyrate concentrations occurred between 0.25 and 3 h after dose, increased with dose, and ranged from 0 to 0.45 mM; peak concentrations did not increase in three patients who had dose escalation.

Phase I clinical trial — solid tumors (three-times-daily dosing, 2003): A subsequent Phase I study published in Cancer Chemotherapy and Pharmacology (2003) escalated to a three-times-daily schedule. Twenty patients with advanced solid tumors for whom no other therapy was available were enrolled; they were treated with tributyrin at doses from 150 to 200 mg/kg three times daily. There was no dose-limiting toxicity; escalation was halted at the 200 mg/kg three times daily level due to the number of capsules required. A median butyrate concentration of 52 µM was obtained but there was considerable interpatient variability. No objective responses were seen. There were four patients with prolonged disease stabilization ranging from 3 to 23 months; median progression-free survival was 55 days. Two patients with chemotherapy-refractory non-small-cell lung cancer had survived for >1 year at the time of the report without evidence of progression. Tributyrin was well tolerated and levels associated with in vitro activity were achieved with three times daily dosing.

In vitro / cell-line evidence: In a study examining Caco-2 cells (a human colon cancer cell line), tributyrin was more potent in inhibiting growth and inducing cell differentiation than natural butyrate, with the effect further enhanced after addition of physiologic concentrations of dihydroxycholecalciferol [(OH)₂D₃]. The synergistic effect of tributyrin and (OH)₂D₃ in Caco-2 cells was due to tributyrin-induced overexpression of the vitamin D receptor; treatment with tributyrin increased binding of (OH)₂D₃ to its receptor 1.5-fold, without any change in receptor affinity. In vitro and in vivo studies have shown that tributyrin acts on multiple anticancer cellular and molecular targets without affecting non-cancerous cells. These remain primarily preclinical findings; no phase II or III trials of tributyrin in cancer have been published to date.

4.3 Metabolic Disease, Obesity, and Insulin Resistance

The evidence in this area comes primarily from animal models, with no published human randomised controlled trials using tributyrin specifically for metabolic outcomes.

Murine high-fat diet model (2012): A study in PubMed treated C57BL/6 male mice on a high-fat diet with tributyrin at 2 g/kg body weight for 10 weeks. Tributyrin protected mice against obesity and obesity-associated insulin resistance and dyslipidemia without food consumption being affected; it attenuated the production of TNFα and IL-1β by peritoneal macrophages and their expression in adipose tissue. Furthermore, in the adipose tissue, tributyrin reduced the expression of MCP-1 and infiltration by leukocytes and restored the production of adiponectin. These effects were associated with a partial reversion of hepatic steatosis, reduction in liver and skeletal muscle content of phosphorylated JNK, and an improvement in muscle insulin-stimulated glucose uptake and Akt signaling.

Murine obesity model — GPR109A mechanism (2020): A study published in Cells (2020) investigated obese mice. Tributyrin, a prodrug of the SCFA butyrate, was investigated for its ability to improve metabolic and inflammatory profiles in diet-induced obese mice; mice fed a high-fat diet for eight weeks were treated with tributyrin or placebo for another six weeks. Obese mice treated with tributyrin had lower body weight gain and improved insulin responsiveness and glucose metabolism, partly via reduced hepatic triglycerides content. Additionally, tributyrin induced an anti-inflammatory state in the adipose tissue by reduction of IL-1β and TNF-α and increased IL-10, Tregs cells, and M2-macrophages. Moreover, improvement in glucose metabolism and reduction of fat inflammatory states associated with tributyrin treatment were dependent on GPR109A activation.

Butyrate-enriched triglycerides — human crossover study: A double-blind placebo-controlled randomized crossover trial at Maastricht University studied a mixed short-chain triglyceride formulation (not pure tributyrin) in men with overweight/obesity. Fourteen men with overweight/obesity (BMI 25–35 kg/m²) received a liquid high-fat mixed meal test containing either a low (650 mg), medium (1,325 mg), or high dose (2,000 mg) of Akovita SCT or a placebo (sunflower oil) in randomized order. All doses were well-tolerated; the medium dose increased (P<0.05) and the high dose tended to increase (P<0.10) postprandial circulating butyrate, though supplementation did not affect any secondary metabolic outcomes compared to placebo. This study measured a structural analog product (butyrate esterified with long-chain fatty acids), not pure tributyrin, and demonstrates proof-of-concept for butyrate delivery by triglyceride esterification but cannot be directly extrapolated to tributyrin supplementation for metabolic outcomes.

4.4 Alcohol-Related Gut and Liver Injury

A body of preclinical work (all animal models, no human trials) has examined tributyrin in the context of alcohol-related liver disease (ALD). Ethanol exposure causes gut dysbiosis resulting in negative alterations in intestinal fermentation byproducts, particularly decreased luminal butyrate concentrations, which contributes to liver injury.

A study aimed to determine whether prophylactic tributyrin could protect the intestinal barrier and liver in mice during combined chronic-binge ethanol exposure; C57BL/6J mice exposed to 5% v/v ethanol-containing diet for 10 days received a single ethanol gavage (5 g/kg) 9 hours prior to euthanasia, with diets supplemented at 5 mM with tributyrin or glycerol. Prophylactic tributyrin supplementation mitigated effects of combined chronic-binge ethanol exposure on disruption of intestinal tight junction localization and intestinal permeability, and reduced liver injury.

Tributyrin, a butyrate prodrug that can inhibit HDAC activity, attenuates hepatic steatosis and injury; a study examined the beneficial effect of tributyrin/butyrate in attenuating ethanol-induced pathogenic epigenetic mechanisms affecting CPT-1A promoter–histone modifications and gene expression and hepatic steatosis/injury. These alcohol-mediated changes were prevented by oral administration of tributyrin, a butyrate prodrug, thereby reducing fat accumulation and liver injury, indicating a potential therapeutic strategy in the treatment of alcoholic liver disease.

In prior studies in which mice exposed to chronic and chronic-binge ethanol were co-supplemented orally with tributyrin, supplemented mice were protected from proximal colon epithelial barrier disruption, as well as liver injury, inflammation, and oxidative stress, compared to non-supplemented ethanol-exposed mice. All findings in this section are from mouse models; human evidence is absent.

4.5 Neurological Health and the Gut–Brain Axis

Short-chain fatty acids such as butyrate, key signaling molecules that influence the gut-brain axis and modulate inflammatory, mitochondrial, and transcriptional regulatory processes, are attracting interest as potential treatments for neurodegenerative disorders such as Parkinson's disease.

Parkinson's disease — open-label target engagement study: A 2025 open-label study published in Neurotherapeutics constitutes the earliest in-human data on tributyrin in Parkinson's disease. Ten subjects completed [¹¹C]butyrate PET imaging before and after the intervention to assess for treatment-related changes in brain, liver, heart, and gastrointestinal uptake of butyrate, confirming target engagement (i.e., organ-specific changes in butyrate availability). Systemic anti-inflammatory effects were also observed. Exploratory cognitive, motor, and neurobehavioral clinical testing was conducted before and after the supplementation period, identifying associated improvements in cognitive and motor features of Parkinson's disease. Given these findings, tributyrin warrants further investigation via larger, placebo-controlled trials as a potential complementary therapy for Parkinson's disease. This study was unblinded, small (n=10), and lacked a placebo group; the findings are exploratory only.

Major depressive disorder — registered pilot RCT: A protocol paper for a pilot randomised controlled trial registered at PMC (2025) describes a planned study. This study is a double-blind, parallel, 1:1 randomised placebo-controlled trial; its primary aim is to assess the feasibility and acceptability of an 8-week oral supplementation with tributyrin (4 g/day), added to usual treatment with antidepressant medication in 24 patients with mild-to-severe MDD aged 18–65 years. Growing evidence indicates that targeting the gut-brain axis could present new therapeutic opportunities for MDD, given the role of gut microbiota and their metabolites in its pathophysiology; one promising approach involves supplementation with butyrate, a short-chain fatty acid that has demonstrated antidepressant potential in preclinical models of depression. This trial is a protocol publication; results are not yet available.

Animal model — neonatal dysbiosis and brain development: In neonatal antibiotic-induced dysbiosis, reduced fecal SCFAs, disrupted intestinal physiology, and abnormal prefrontal myelination and behavior are partly corrected by oral tributyrin, linking microbiota-derived butyrate to both gut barrier function and CNS structure. This is a preclinical finding.

Signaling through GPR109A (a butyrate receptor) attenuates LPS-induced microglial reactivity and NF-κB levels, which in turn reduces the expression of several inflammatory mediators, such as iNOS, COX-2, TNF-α, IL-1β, and IL-6. Accordingly, butyrate reduces hippocampal microgliosis and improves depressive-like behaviors secondary to neuroinflammation. These mechanistic insights come from preclinical data and have not yet been confirmed in placebo-controlled human studies specifically for tributyrin.

5. Body Systems and Health Areas of Association

• Gastrointestinal system: Colonocyte energetics, intestinal epithelial barrier integrity, tight junction protein regulation, mucin and antimicrobial peptide production, gut microbiome composition (including Bifidobacterium and Akkermansia mucinophila).
• Immune system: Modulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), promotion of anti-inflammatory macrophage polarisation (M2), regulatory T-cell (Treg) expansion, toll-like receptor signalling.
• Hepatic system: Protection against alcohol-induced hepatic steatosis, HDAC inhibition affecting CPT-1A gene expression in the liver, reduction of liver injury markers (AST).
• Metabolic system: Insulin sensitivity, glucose metabolism, adipose tissue inflammation, dyslipidemia — studied in animal models only for tributyrin specifically.
• Oncology: Induction of differentiation and apoptosis in neoplastic cells via HDAC inhibition and Warburg effect reversal — primarily in vitro and early-phase clinical data.
• Neurological/CNS system: Gut-brain axis signalling, blood-brain barrier integrity, neuroinflammation — primarily preclinical with early human pilot data in Parkinson's disease.
• Pulmonary system: Excessive alcohol consumption increases the severity and worsens outcomes of pulmonary infections, often due to oxidative stress and tissue damage, with recent evidence suggesting ethanol-induced changes to the gut microbiome impact the gut-lung axis; tributyrin has been studied in this context in mouse models only.

6. Dosage Forms and Reported Dosages

Tributyrin is available commercially in the following delivery forms:

• Oral capsules (e.g., hard capsules and softgels)
• Liquid formulations (given that pure tributyrin is a liquid at room temperature)
• Microencapsulated powders (for food/feed applications)

The following dosages have been reported in published studies:

• Phase I oncology trial (once-daily, 1998): 13 patients received escalating doses of tributyrin from 50 to 400 mg/kg/day.
• Phase I oncology trial (three-times-daily, 2003): 20 patients with advanced solid tumors were treated with tributyrin at doses from 150 to 200 mg/kg three times daily.
• Healthy adult supplement pilot RCT (2024): Participants ingested one or two (200 or 400 mg, respectively) ButyraGen® capsules daily for 21 days.
• MDD pilot RCT protocol (registered 2025): Tributyrin 4 g/day for 8 weeks as add-on to antidepressant therapy is the planned dose in 24 patients with MDD.
• Butyrate-enriched triglyceride crossover study (Maastricht, published in PMC): Participants received a liquid high-fat mixed meal test containing either a low (650 mg), medium (1,325 mg), or high dose (2,000 mg) of the SCFA-enriched triglyceride formulation.
• Preclinical high-fat diet murine study: C57BL/6 male mice fed a standard chow or high-fat diet were treated with tributyrin at 2 g/kg body weight for 10 weeks.
• Preclinical alcohol-related model: Tributyrin was supplemented at concentrations of 0.83 to 10 mM, either into the liquid diet or by oral gavage.

No regulatory authority (FDA, EFSA, EMA) has established a recommended dietary intake or tolerable upper limit for supplemental tributyrin. The supplement doses studied in healthy adults (200–400 mg/day) are substantially lower than the pharmacological doses used in oncology trials.

7. Safety Considerations and Interactions

Tolerability in Human Studies

No other notable changes in endpoints were observed in the pilot RCT; tributyrin supplementation using ButyraGen® was safe and tolerable at the doses provided. The extremely high amounts of butyrate or butyrate precursor used in cancer trials would not be acceptable for acute or chronic daily supplementation for maintenance of health; the pilot RCT demonstrated that ButyraGen® is a promising tributyrin-containing complex that can be taken daily at a safe and tolerable level.

Adverse Effects at Pharmacological (Oncology) Doses

At oncology-level doses (50–400 mg/kg/day), grade 3 toxicities consisted of nausea, vomiting, and myalgia; grades 1 and 2 toxicities included diarrhea, headache, abdominal cramping, nausea, anemia, constipation, azotemia, lightheadedness, fatigue, rash, alopecia, odor, dysphoria, and clumsiness. In the three-times-daily Phase I trial, there was no dose-limiting toxicity; escalation was halted at the 200 mg/kg three-times-daily level due to the number of capsules required. These toxicity profiles pertain specifically to extremely high oncological doses and should not be extrapolated to dietary supplement doses.

Pharmacokinetic Safety Observations

Once butyrate enters circulation, its half-life is measured in minutes. The major pharmacological challenge has been to achieve and maintain millimolar concentrations in blood; butyrate is metabolized rapidly as soon as it enters the colonocyte via its active transport system, and its plasma concentrations are far below those required to exert antiproliferative/differentiating actions.

Organoleptic Properties Relevant to Tolerability

Unlike free butyric acid, which is volatile and has an unpleasant odor, tributyrin is odorless and more resistant to degradation, making it suitable for controlled butyrate delivery. This is a relevant tolerability advantage over salt forms for long-term supplementation.

Concentration-Dependent Effects

Butyrate stimulates various receptors and inhibits HDAC in different cell types, thus stabilizing the gut barrier function and decreasing inflammatory processes; however, some studies indicate contrary effects according to butyrate concentrations. This context-dependence is relevant for establishing appropriate dose ranges.

Interactions and Special Populations

No specific drug interaction data for tributyrin as a dietary supplement have been published in peer-reviewed literature at the time of this writing. In the Phase I oncology trial, there was no consistent increase in hemoglobin F with tributyrin treatment, suggesting the haemoglobin-inducing effect hypothesised from earlier butyrate research in haemoglobinopathies was not confirmed at the doses tested. Butyrate supplementation has been evaluated in clinical studies in patients with a variety of conditions, including inflammatory bowel disease, pediatric obesity, lead-induced neuroinflammation, cancer, and chronic obstructive pulmonary disease, indicating that the broader butyrate class has been evaluated across diverse clinical contexts, though most of this literature pertains to salt forms rather than tributyrin specifically.

Overall Evidence Characterization

The totality of evidence for butyrate triglyceride (tributyrin) as a dietary supplement for human health is at an early stage. The most robust human data concern safety and pharmacokinetics at pharmacological (oncological) doses. Evidence for gut health, metabolic, neurological, and anti-inflammatory benefits comes predominantly from animal studies and in vitro models. The sole randomised human study in healthy adults (n=29, 28 days) was a pilot with a small sample. A Parkinson's disease open-label target engagement study (n=10) provides early neurological signal data. The registered MDD pilot trial had not yet reported results at the time of this writing. No human RCT data exist for metabolic, hepatic, or oncological endpoints at nutritional doses. In ulcerative colitis as an adjunct to standard therapy, the IBD-trial evidence for the butyrate class is positive; for general "gut health" in healthy adults, controlled human evidence is sparse, and dietary fermentable fiber has a broader evidence base than supplementation.

References

• Palma et al. (2023). Tributyrin supplementation in fish and crustacean nutrition: A review. Reviews in Aquaculture, 15(2), 785–800.
• Wikipedia. Tributyrin.
• Conley BA, et al. (1998). Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clinical Cancer Research, 4(3), 629–634.
• Edelman MJ, et al. (2003). Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemotherapy and Pharmacology.
• Frontiers in Nutrition / PMC (2025). Tributyrin (CoreBiome®) enhances butyrate levels and modulates the gut microbiota, barrier function, and immune response in vitro.
• Smith M, et al. (2024). Investigation of the tolerability and potential health benefits of a novel butyrate generating supplement in a pilot human study. Nutrition and Health Aging.
• Vinolo MAR, et al. (2012). Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice. PubMed.
• Sato FT, et al. (2020). Tributyrin Attenuates Metabolic and Inflammatory Changes Associated with Obesity through a GPR109A-Dependent Mechanism. Cells, 9(9), 2007.
• Cresci GA, et al. (2014). Tributyrin Supplementation Protects Mice from Acute Ethanol-Induced Gut Injury. Alcoholism: Clinical and Experimental Research, 38, 1489–1501. PMC4185400.
• Cresci GA, et al. (2017). Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury. PMC5511097.
• Glueck B, Han Y, Cresci GAM (2018). Tributyrin Supplementation Protects Immune Responses and Vasculature and Reduces Oxidative Stress in the Proximal Colon of Mice Exposed to Chronic-Binge Ethanol Feeding. PMC6120279.
• Zakhari S, et al. (2020). Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury. PMC7078548.
• Cresci GAM, et al. (2024). Tributyrin Supplementation Rescues Chronic–Binge Ethanol-Induced Oxidative Stress in the Gut–Lung Axis in Mice. PMC11047693.
• Janssen AWF, et al. (2023). Butyrate and hexanoate-enriched triglycerides increase postprandrial systemic butyrate and hexanoate in men with overweight/obesity: A double-blind placebo-controlled randomized crossover trial. PMC9846253.
• Neurotherapeutics (2025). Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study.
• PMC (2025). Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study. PMC12976542.
• PMC (2025). Feasibility and acceptability of 8-week oral tributyrin supplementation as add on to antidepressant medication in patients with depression: a study protocol paper for a pilot, randomised controlled trial. PMC12587968.
• Donohoe DR, et al. (2021). Butyrate and the Intestinal Epithelium: Modulation of Proliferation and Inflammation in Homeostasis and Disease. PMC8304699.
• Rivière A, et al. (2021). Butyrate and the Fine-Tuning of Colonic Homeostasis: Implication for Inflammatory Bowel Diseases. PMC8002420.
• PMC (2025). A comprehensive review of usefulness of sodium butyrate for the management of inflammatory bowel disease: from molecular mechanisms to clinical application. PMC13085030.
• Parada-Venegas D, et al. (2025). Butyrate suppresses mucosal inflammation in inflammatory bowel disease primarily through HDAC3 inhibition in monocytes and macrophages. The FEBS Journal.
• Frontiers in Nutrition (2022). Protective role of butyrate in obesity and diabetes: New insights.
• Gaschott T, Stein J (2001). Tributyrin, a Stable and Rapidly Absorbed Prodrug of Butyric Acid, Enhances Antiproliferative Effects of Dihydroxycholecalciferol in Human Colon Cancer Cells. Journal of Nutrition. ScienceDirect.
• Frontiers in Medicine (2021). Histone Deacetylases in the Inflamed Intestinal Epithelium—Promises of New Therapeutic Strategies.
• Cleveland Clinic (2022). What Is Butyrate? Benefits and Side Effects.